The CXCL13/CXCR5-axis, with its prominent role in launching adaptive immune responses and its circulating soluble and cellular components, could be an additional promising resource for anti-cancer biomarker research in immunogenic tumors, such as melanoma. This evidence concerns the gene CXCR5 and melanoma.